PHAR

11.5405.18%
LK

Leonard Kruimer

Independent Non-Executive Director

Mr. Leonard Kruimer, M.B.A, C.P.A, also known as Leon, is Independent Non-Executive Director of Basilea Pharmaceutica AG from April 13, 2022. He served as an Independent Director at Oncolytics Biotech Inc. since October 2, 2019 until June 16, 2022. He serves as Non-Executive Director at Pharming Group N.V. since May 19, 2021. He has been Chairman of the Board of BioInvent International AB and its Director since 2018. He serves as an Independent Director at Zealand Pharma A/S since April 4, 2019. He served as the Chief Financial Officer at SkylineDx B.V. since August 15, 2015. Mr. Kruimer served as the Chief Financial Officer at BBB Therapeutics BV since January 2014 and served as its Acting Chief Executive Officer until September 9, 2014. He has extensive experience in accounting, corporate finance, planning and strategy, including senior executive positions in private and publicly listed biotechnology companies like Crucell. He serves as Director at Advent Int. Global Investments and advisor to private equity firm Karmijn Kapitaal Investments. His professional career spans both the diagnostic and pharmaceutical industries. He served as the Chief Financial Officer and Acting Chief Executive Officer of to-BBB Holding B.V. He served as the Chief Financial Officer and Member of Management Board at Crucell N.V. from 1998 to 2011 and was responsible for financing the Crucell in private and public markets, including the IPO at Nasdaq and Euronext in 2000 and subsequent listing on the Swiss Stock Exchange in 2006. He served as Chief Financial Officer of IntroGene from 1998 to 2000. From 1996 to 1998, he served as an Independent Consultant with Pepsico and Royal Boskalis Westminster N.V. Prior to Crucell, he served as Managing Director at TIP Europe, a unit of GE Capital. From 1988 to 1995, he held Senior Executive positions at Continental Can Europe and Kwik-Fit Europe B.V. He served as a Consultant at McKinsey & Co. and has worked with Price Waterhouse & Co in New York. He served as the Chairman of the Supervisory Board of ProFibrix, BV. from 2011 to 2013 and served as its Member of Supervisory Board from May 2011 to 2013. He served as a Director of BioInvent International AB since May 23, 2016 until 2017. Mr. Kruimer holds a Master’s in Business Administration from Harvard Graduate School of Business Administration and a BA in accounting and finance from University of Massachusetts and is a CPA in New York State.

Positions